Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price Target at $19.67

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has received a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $19.67.

A number of equities research analysts have weighed in on TEVA shares. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $16.59 on Friday. The stock has a market cap of $18.79 billion, a PE ratio of -19.40, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The firm’s 50-day simple moving average is $17.65 and its two-hundred day simple moving average is $17.36.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $50,000. Sanctuary Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after purchasing an additional 664 shares in the last quarter. TCW Group Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $1,286,000. Geode Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 3.4% in the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after purchasing an additional 291,124 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company’s stock worth $7,705,000 after purchasing an additional 102,848 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.